Abstract:Abstract Introduction. PredicineCARE is a CLIA-certified targeted next-generation sequencing (NGS) assay that provides comprehensive, non-invasive genomic profiling of circulating tumor DNA (ctDNA) in blood and urine. Here we present liquid biopsy mutational profiles and genome-wide cell-free DNA (cfDNA) copy-number burden levels for historical cancer cohorts analyzed with PredicineCARE. We include a total of 3,147 samples from six major cancer indications: prostate (n=1681), lung (n=630), breast (n=300), colorectal (n=217), pancreatic (n=190), and bladder (n=129). Methods. PredicineCARE employs a 152 targeted gene panel covering all major guideline-recommended alterations for patient care and clinical drug development including targeted therapies and immunotherapies. The assay detects single nucleotide variants (SNVs), small insertions and deletions, gene-level copy number loss/gain, and targeted re-arrangements/fusions. Concurrent low-pass whole-genome sequencing (without the need for additional sample volume) is performed to measure blood-based genome-wide copy-number burden (bCNB) and tumor fraction, providing important complementary molecular insights to variant detection. Results. We present data from a representative cohort of blood and urine samples processed at Predicine lab in Hayward California (n=3,147). Sequencing was performed using a minimum of 5 ng total cfDNA input from 1-5 mL of plasma or 20-40mL of urine, at one or more clinical timepoints per patient. Samples were sequenced at ~20,000X target panel coverage and the majority also had ~2.5X low-pass whole genome sequencing. Using the Predicine in-house DeepSea bioinformatics pipeline, we report variants as low as 0.05% allele frequency and estimate genome-wide CNVs and bCNB from low-pass data. We compare the mutational and CNV profiles of important genes in each liquid biopsy cancer cohort to variants reported in solid tumor tissues from several large public data sets including Project GENIE (n=71,817 patients) and 136 additional study programs including TCGA (n=38,619 patients, www.cBioPortal.org). Conclusion. PredicineCARE is a highly sensitive and robust assay for detecting cancer variants in blood and urine. The cfDNA mutation profiles are mostly consistent with public tissue datasets. A small but significant portion of the detected ctDNA variants have been shown to be important for treatment selection or are currently being tested for targeted drug development. Increased bCNB provides a useful measure to monitor treatment response and disease progression. PredicineCARE has been CE-marked and received breakthrough device designation from FDA. A harmonized PredicineCARE assay is available in the US and China to support patient testing in the clinic, global clinical trials and CDx development. Citation Format: Billie Gould, Lu Tan, Chao Dai, Tiantian Zheng, Wei Mo, Xianghong Wang, Michael Sneddon, Shidong Jia, Kemin Zhou, Pan Du. Targeted liquid biopsy mutation profiling and genome-wide cfDNA copy-number landscape in 3000 samples from six major cancer indications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6685.

Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance.

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Clinical Utility of an Ultra-Sensitive Ctdna NGS Assay for the Detection and Monitoring in HR-positive, HER2-negative Breast Cancer.

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

An Ultra-Deep Next Generation Sequencing Method for Cfdna Detection in Nsclc Patients.

2262P Baseline-informed Versus Tumor-Agnostic Minimal Residual Disease (MRD) Concordance Study in Patients with HER2+ Gastroesophageal Adenocarcinoma Patients

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy

Abstract LB547: Ultra-deep targeted sequencing of circulating tumor DNA with colorectal cancer patients for prediction of treatment response and post-surgical follow-up

Abstract 6685: Targeted Liquid Biopsy Mutation Profiling and Genome-Wide Cfdna Copy-Number Landscape in 3000 Samples from Six Major Cancer Indications

Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in non-small cell lung cancer.

P1.01-037 Circulating Tumor DNA Clearance During Treatment Associates with Improved Progression-Free Survival

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Tracking MRD and Neoantigen Targets Using a Tumor-Informed Liquid Biopsy Platform in HCC Patients Treated with Personalized Cancer Vaccine and Pembrolizumab.

Advancing cancer MRD monitoring through tumor whole-genome informed, duplex ctDNA sequencing.

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay

Association of Circulating Tumor DNA Clearance During Treatment with Improved Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients.

Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial

Technical And Clinical Validation Of Somatic Cnv Detection From Circulating Tumor Dna.

Abstract 2281: The role of baseline and early dynamics of ctDNA in predicting response and prognosis of early and advanced gastroesophageal adenocarcinomas

Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management